Literature DB >> 28706359

Medical Management of Symptomatic Fibroids: Worth It?

Chandrashekhar V Hegde1.   

Abstract

Year:  2017        PMID： 28706359      PMCID： PMC5491416          DOI： 10.1007/s13224-017-1020-5

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN： 0975-6434


× No keyword cloud information.
  24 in total

Review 1.  The role of progesterone signaling in the pathogenesis of uterine leiomyoma.

Authors:  J Julie Kim; Elizabeth C Sefton
Journal:  Mol Cell Endocrinol       Date:  2011-06-06       Impact factor: 4.102

2.  Long-term medical management of uterine fibroids with ulipristal acetate.

Authors:  Jacques Donnez; Olivier Donnez; Dace Matule; Hans-Joachim Ahrendt; Robert Hudecek; Janos Zatik; Zaneta Kasilovskiene; Mihai Cristian Dumitrascu; Hervé Fernandez; David H Barlow; Philippe Bouchard; Bart C J M Fauser; Elke Bestel; Ernest Loumaye
Journal:  Fertil Steril       Date:  2015-10-23       Impact factor: 7.329

3.  Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy.

Authors:  M Nisolle; S Gillerot; F Casanas-Roux; J Squifflet; M Berliere; J Donnez
Journal:  Hum Reprod       Date:  1999-11       Impact factor: 6.918

Review 4.  GnRH agonists and uterine leiomyomas.

Authors:  F J Broekmans
Journal:  Hum Reprod       Date:  1996-11       Impact factor: 6.918

5.  Ulipristal acetate for pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands: cost minimization analysis and budget impact analysis.

Authors:  N Zakiyah; A D I van Asselt; M J Postma
Journal:  J Med Econ       Date:  2016-11-11       Impact factor: 2.448

Review 6.  Non-surgical management of uterine fibroids.

Authors:  Giovanna Tropeano; Sonia Amoroso; Giovanni Scambia
Journal:  Hum Reprod Update       Date:  2008-03-14       Impact factor: 15.610

7.  Development of the selective progesterone receptor modulator CDB-2914 for clinical indications.

Authors:  Diana L Blithe; Lynnette K Nieman; Richard P Blye; Pamela Stratton; Maureen Passaro
Journal:  Steroids       Date:  2003-11       Impact factor: 2.668

Review 8.  [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].

Authors:  Marian Szamatowicz; Jan Kotarski
Journal:  Ginekol Pol       Date:  2013-03       Impact factor: 1.232

Review 9.  Ulipristal acetate: in uterine fibroids.

Authors:  Jamie D Croxtall
Journal:  Drugs       Date:  2012-05-28       Impact factor: 9.546

10.  Different dosages of mifepristone versus enantone to treat uterine fibroids: A multicenter randomized controlled trial.

Authors:  Chongdong Liu; Qi Lu; Hong Qu; Li Geng; Meilu Bian; Minli Huang; Huilan Wang; Youzhong Zhang; Zeqing Wen; Shurong Zheng; Zhenyu Zhang
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.